Sir,

The recent publication on the recombinant human bone morphogenetic protein-2 (rhBMP-2) is very interesting.\[[@ref1]\] Hamilton *et al*. concluded that "100% fusion rate was achieved with adjunct use of rhBMP-2, with a safe and effective average rhBMP-2 dose of 2.38 mg per level."\[[@ref1]\] Indeed, the use of rhBMP-2 is a new approach and the important concern is on the supporting evidences on this technique.\[[@ref2]\] In this work, the total number of subjects is small; however, it can be a good supporting evidence. Another important concern is on the adverse effect of using this technique. Addullah *et al*. noted for the necessity on good examination with regard to side effect profiles.\[[@ref2]\] Taghavi *et al*. noted that the "utility is limited by cost, and potential dose-dependent risks, such as local inflammatory reactions and ectopic bone formation."\[[@ref3]\] An important side effect that is observed in the animal model studies is "joint space obliteration caused by cartilage overgrowth."\[[@ref4]\] This has to be systematically evaluated in the long-term follow-up.
